The association between homocysteine and sustained hypertension (HT) has been studied. The aim of this study was to assess homocysteine levels in white coat hypertension (WCH) as an indicator of increased risk in the development of cardiovascular diseases. WCH was defined as clinical hypertension and a daytime ambulatory blood pressure of < 135/85 mmHg. Plasma levels of homocysteine were determined in patients with WCH, hypertension, and normotension (NT). The study group included 100 subjects, 33 with WCH (16 males, 17 females) aged 49.1 ± 1.9; 35 sustained hypertensives (17 males,18 females) aged 48.5 ± 1.7 and 32 normotensive control subjects (15 males, 17 females) aged 48.8 ± 2.2. The subjects were matched for age, gender, and body mass index. Patients with a smoking habit, dyslipidemia, or diabetes mellitus were not included in the study. Homocysteine levels were analyzed by ELISA. Plasma homocysteine levels were significantly higher in the WCH group compared to the controls (12.32 ± 1.07 versus 5.35 ± 1.38 µmol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 ± 0.76 µmol/L P < 0.001). Total cholesterol and triglycerides were not different among the groups. There were no statistically significant differences in urinary albumin excretion (UAE) or creatinine clearence between the three groups. Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs. LVMI was greater in the WCH group compared to the NTs, but significantly less than HTs.
SUBJECTS with white coat hypertension (WCH) are characterised by elevated arterial pressures in the physician's office, but 'normal' pressures at other times. The outcome for white coat hypertension is not yet completely clear. Several studies have indicated a good prognosis for this condition by demonstrating a low-degree of end organ damage, [1] [2] [3] whereas other authors have reported endorgan damage 4, 5) and metabolic abnormalities such as hyperlipidemia, impaired insulin sensitivity, elevated blood glucose, and increased serum insulin [6] [7] [8] levels in patients with WCH.
Sustained hypertensive patients (HT) are at particular risk of cardiovascular complications, possibly related to endothelial damage or dysfunction, or to abnormal angiogenesis. More and more attention is being paid to endothelial dysfunction in the pathogenesis of hypertension.
The elevation of homocysteine levels is now known as an independent risk factor for vascular diseases. [9] [10] [11] [12] [13] [14] [15] [16] Homocysteine promotes oxidant injury to the vascular endothelium, impairs endothelium-dependent vasomotor regulation, and may also alter the coagulant properties of the blood.
The association between homocysteine and sustained hypertension has been investigated, [9] [10] [11] [12] [13] [14] [15] and it is thought that an interaction between homocysteine and endothelium in hypertensive patients may promote thrombogenesis and atherogenesis, leading to adverse cardiovascular events. 16) To the best of our knowledge, only one study has evaluated homocysteine levels in WCH.
17) The aim of this study was to assess homocysteine levels in WCH as a marker of cardiovascular risk.
METHODS
The study group consisted of 100 subjects, 33 with WCH, 35 sustained hypertensives (HT), and 32 normotensive control subjects (NT). The subjects did not have any other risk factor for atherosclerosis except high blood pressure. The exclusion criteria were hyperlipidemia (LDL > 130 mg), any signs or symptoms of atherosclerotic vascular disease, diabetes mellitus, or other endocrine disease, obesity (BMI > 27), drugs that may affect blood pressure or lipid metabolism, smoking, and alcoholism. All patients were free of concomitant vascular disease, malignancy, and renal and connective tissue diseases. They were all physically active and were not using any vitamin supplement. The female patients were postmenopausal. Subjects were administered a low-nitrate diet for two days before the measurements.
Brachial arterial pressure measurements in patients referred to our clinic due to high blood pressure (diastolic pressure > 90 mmHg) were obtained in our outpatient department by a nurse with a mercury sphygmomanometer which was standardized in accordance with the American and British Hypertension Society and World Health Organisation. Measurements were obtained with the subject in the sitting position after resting for 20-30 minutes. [18] [19] [20] Korotkoff phase I was used to determine the systolic pressure and phase V for diastolic pressure. Measurements were performed on three different days within five days. Three blood pressure readings were taken per session and averaged and then subsequently averaged once more over 3 sessions. An ambulatory 24-hour arterial blood pressure recording was performed in the patients whose diastolic pressure was found to be higher than 90 mmHg in the outpatient department, with an instrument (A and D Engineering, TM-2421) approved and suggested by the European Hypertension Society. 21) Measurements were performed on the left arm as suggested by the British Hypertension Society. 22) According to the results of the ambulatory measurement patients were classified into sustained or white coat hypertension groups. White coat hypertension was defined as clinical hypertension and a daytime ambulatory blood pressure less than 135/85 mmHg. Patients with a daytime ambulatory diastolic blood pressure greater than 85 mmHg were included in the hypertensive group.
All patients underwent blood and urine analysis, fundoscopy, and a standard echocardiographic examination. L-homocysteine: A commercially available ELISA (AXIS R Homocysteine EIA package insert) was used for the measurement of total L-homocysteine in blood. Protein bound homocysteine is reduced to free homocysteine and enzymatically converted to S-adenosyl-L-homocysteine (SAH) in a separate procedure prior to the immunoassay. The enzyme is specific for the L-form of homocysteine, which is the only form present in the blood. The calibrator range is 2-50 mmol/L. The quantification limit of the homocysteine is 1 mmol/L with a CV < 20%. The blood samples were obtained in a fasting condition lasting at least ten hours. Biochemical analysis: Serum total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG), low-density lipoprotein (LDL), and 24-hour creatinine clearance were measured using standard enzymatic methods and a fully automated analyzer (Olympus AU-800). Blood samples were taken after an overnight fast. Microalbuminuria over 24 hours was measured by radioimmunoassay (RIA). Urinary albumin excretion (UAE) between 30 and 300 mg/day was taken as microalbuminuria.
Fundoscopic classification of hypertensive retinopathy (HTRP) was performed by an experienced ophthalmologist according to the Keith, Wagener and Barker classification.
23)
Echocardiography: Left ventricular end-diastolic posterior wall thickness, interventricular septal wall thickness at end diastole, left ventricular internal end-diastolic diameter (LVIDD), and left ventricular internal end-systolic diameter (LVIDS) were measured using the American Society of Echocardiography convention from M-mode images of the left ventricle, generated in the short axis view at the level of the mitral chordea (2.5 MHz; Hewlett Packard 2500). Using these measurements, left ventricular mass (LVM) and left ventricle mass index (LVMI) were calculated. 24, 25) Statistical analysis: Data are expressed as the mean ± SD. The groups were compared with Anova Tukey HSD. A P value < 0.05 was considered to be significant.
RESULTS
The basic characteristics of the groups are given in Table I . Thirty-two normotensives (15 males, 17 females), 33 white coat hypertensives (16 males, 17 females), and 35 hypertensives (17 males, 18 females) were included in the study. The mean age was similar in the normotensive, white coat hypertensive, and sustained hypertensive groups (48.8 ± 2.2; 49.1 ± 1.9 and 48.5 ± 1.7). BMI also showed no significant difference between the groups (24.8 ± 0.7; 25 ± 0.9 and 25.2 ± 0.9). Table II shows the clinical and ambulatory blood pressure mean values in the normotensive, white coat hypertensive, and sustained hypertensive groups. In ambulatory daytime measurements, mean systolic pressures were 126 ± 4, 131 ± 3, and 157 ± 9 mmHg and mean diastolic pressures were 81 ± 3; 82 ± 6, and 95 ± 5 mmHg respectively. Both the systolic and diastolic pressures in the WCH group were significantly different from the HT group (131 ± 3 versus 157 ± 9; P < 0.001 and 82 ± 6 versus 95 ± 5, P < 0.001). Patients with WCH had systolic and diastolic ambulatory daytime blood pressure values that were similar to those of normotensives (131 ± 3 versus 126 ± 4; P = 0.162 and 82 ± 6 versus 81 ± 3; P = 0.712). The nighttime SBP and DBP of the HT group were significantly different from the NT and WCH group (P < 0.001). The nighttime SBP of NTs was different from WCHs (P < 0.001). In the normotensive, white coat hypertensive, and sustained hypertensive groups, averaged systolic blood pressures during 24 hour ambulatory blood pressure monitoring were 118 ± 4, 122 ± 5, and 158 ± 10 mmHg while the diastolic pressures were 73 ± 4, 75 ± 3, and 94 ± 6 mmHg, respectively. Table III summarizes the biochemical characteristics of the study groups. Subjects with hyperlipidemia (LDL > 130 mg/dL) were not included in the study. Cholesterol and triglyceride levels were not different among the groups. Both the WCH and HT groups had high levels of UAE (34.6 ± 7.4 and 34.8 ± 7.9 mg/day, respectively), but the differences between the groups were not significant. There was no statistically significant difference in creatinine clearance among the three groups. NT = normotensives; WCH = white coat hypertensives; HT = hypertensives; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; VLDL-C = very-low-density lipoprotein cholesterol; GFR = glomerular filtration rate; UAE = urinary albumin excretion.
Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs (21% versus 46%) (Table IV) .
LVMI was greater in the WCH group compared to the NTs (93 ± 25 versus 79 ± 13 g/m 2 ; P = 0.001), but significantly less than the HTs (103 ± 26 g/m 2 ; P = 0.005).
Plasma homocysteine levels were significantly higher in the WCH group compared to the normotensives (12.32 ± 1.07 versus 5.35 ± 1.38 µmol/L; P < 0.001) and the WCH group had significantly lower homocysteine values than the hypertensives (19.03 ± 0.76 µmol/L, P < 0.001) ( Table V) .
Nighttime SBP in the NT group was significantly different from the WCH group (P < 0.001). There was a positive correlation between nighttime SBP and homocysteine (r = 0.846; P = 0.01). We evaluated the difference in homocysteine levels between NT and WCH after matching the level of nighttime BP. The NT group consisted of 27 subjects and nighttime SBP was 105 ± 4 mmHg. The WCH group consisted of 28 subjects and nighttime SBP was 107 ± 5 mmHg. After matching for nighttime SBP, the homocysteine level was 5.56 ± 1.12 µmol/L in NT and 11.96 ± 1.03 µmol/L in WCH (P < 0.001). 
DISCUSSION
Hyperhomocysteinemia has been linked to hypertension. 11, 16) Even mild hyperhomocysteinemia is a major risk factor for arterial vascular disease, independent of conventional risk factors, such as diabetes mellitus, cigarette smoking, or hyperlipidemia. [26] [27] [28] The mechanism may be related to impairment of vascular endothelial and smooth muscle cell function. It has been suggested that hyperhomocysteinemia diminishes vasodilatation by nitric oxide, increases oxidative stress, alters the elasticity of the vascular wall, and contributes to elevate the blood pressure. 28) Human studies have shown that high levels of homocysteine are associated with impaired endothelial-dependent vasodilatation in essential hypertension. It has been thought that an interaction between homocysteine and endothelium in hypertensive patients may promote thrombogenesis and atherogenesis, leading to adverse cardiovascular events. 16, 26, 28) However, the Framingham Heart Study found no major relation between baseline homocysteine levels and hypertension incidence or longitudinal blood pressure progression in a large cohort of nonhypertensive individuals. 29) Stehouwer, et al suggested that the hypothesis that homocysteine increases blood pressure must be considered unproven. 30) Homocysteine levels in WCH patients have been inadequately studied. Our data showed that patients with WCH have significantly higher homocysteine levels than normotensive subjects, but significantly lower levels than hypertensives. Pierdomenico, et al reported that white coat hypertensive subjects had significantly lower homocysteine levels than sustained hypertensive patients. 31) Contrary to our findings, however, no significant difference was observed between white coat hypertensive and normotensive subjects regarding this parameter. Their data showed that middle-aged white coat hypertensive subjects without other cardiovascular risk factors have lower circulating homocysteine levels than sustained hypertensive patients, suggesting that they are at lower cardiovascular risk. Mean age in their study was similar to ours, but the duration of WCH can not be defined for either study. As the duration of WCH increases, endothelial function can become impaired, such as for sustained hypertension. In their study, homocysteine levels were evaluated by fluorescence polarization immunoassay. In our study, ELISA was used for the measurement of homocysteine. Brunelli, et al evaluated three different methods for homocysteine determination: high-pressure liquid chromatography (HPLC) (considered as the reference method) and two commercial immunoassays, an enzyme-linked immunoassay (ELISA) and automated fluorescence polarization immunoassay (FPIA). Their results indicated that the two methods correlated well with the reference method, although the technological characteristics of the FPIA assay make it more suitable for homocysteine determination in clinical laboratories. 32) Although ELISA is also suitable for homocyteine measurement, the difference between their study and ours might be due to the different methods used.
Kahleova, et al 33) examined the presence of insulin resistance and disturbed homocysteine metabolism in young adults at the early stages of essential hypertension. They showed that essential hypertension in adolescents is associated with higher homocysteine levels and signs of insulin resistance. In a population based study, Bjorklund, et al reported of insulin resistance in WCH and indicated that a lower body mass index and more favorable dietary fat composition predicted the development of white-coat hypertension as opposed to sustained hypertension over 20 years. 34) In our study and in the study of Pierdomenico, et al the presence of insulin resistance which modifies the homocysteine levels was not evaluated. This is a possible limitation of the two studies.
Results from studies focusing on end-organ damage in WCH indicate an intermediate status for WCH between normotensives and sustained hypertensives. Hoegholm reported that white coat hypertensives have less renal involvement (microalbuminuria) than patients with established hypertension, but more than normotensive controls. 5) In our study both the WCH and HT groups had high levels of UAE, however, the differences between the groups were not significant. There were no statistically significant differences in creatinine clearence between the three groups.
Hypertensive retinopathy was observed in the WCH group, but was less severe and less frequent compared to HTs.
Although an earlier study by White, et al evaluating LV filling rate at rest and ejection fraction at peak exercise reported similar results for WCH and normotensives, a more recent study by Cardillo, et al showed that the LV mass index and diastolic filling parameters of WCH displayed abnormalities similar to those of the persistent hypertensive group compared with normotensives. 3, 4) In our study, LVMI was greater in the WCH group compared to NTs, but significantly less than HTs. The target organ status of our patients with WCH suggest that patients with WCH represent an intermediate group between normotensives and sustained hypertensives when target organ damage is concerned.
In conclusion, this is the first report showing increased homocysteine levels in WCH. Since an elevated plasma homocysteine level is a strong risk factor for coronary artery disease, WCH should perhaps not be considered an innocent trait. Further studies are needed to assess the increased cardiovascular risk conferred by high homocysteine levels in WCH.
